Archive for the ‘Depression’ Category

Non-Invasive Treatment For Depression - Rush University Medical Center Psychiatrist Led Clinical Trials Of Transcranial Magnetic Stimulation

Friday, October 10th, 2008
Transcranial Magnetic Stimulation (TMS) therapy has received clearance from the U.S. Food and Drug Administration (FDA) and is now an entirely new treatment option for patients suffering from depression. Dr.

FDA Clears Neurostar® TMS Therapy For The Treatment Of Depression

Thursday, October 9th, 2008
Neuronetics, Inc., a privately-held medical device company and a leader in the field of neuromodulation, announced today that the U.S. Food and Drug Administration (FDA) has cleared its NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy system for the treatment of depression.

An Animal Model Of Behavioral Intervention For Depression

Thursday, October 9th, 2008
A new animal model has provided insight into the cellular and molecular mechanisms associated with behavioral therapy for depression. The study, published by Cell Press in the October 9th issue of Neuron, may provide a good model system for testing cellular and molecular interactions between antidepressive medications and behavioral treatments for depression.

St. John’s Wort Helps Some Patients With Major Depression

Thursday, October 9th, 2008
The herbal medicine St. John's wort appears to work just as well as some prescribed antidepressants for treating patients with major depression, a new review finds. However, patients in German-speaking countries might experience the best benefits. While there is public interest in the United States about whether St.

FDA Clears NeuroStar(R) TMS Therapy For The Treatment Of Depression

Thursday, October 9th, 2008
Neuronetics, Inc., a privately-held medical device company and a leader in the field of neuromodulation, announced today that the U.S. Food and Drug Administration (FDA) has cleared its NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy system for the treatment of depression.

Researchers Concerned That Depression Is Unrecognized In Physician-Assisted Suicides

Thursday, October 9th, 2008
According to a study published on bmj.com, Oregon's Death with Dignity Act may not be adequately protecting the 25% of terminally ill patients in the State of Oregon who have depression and then choose physician assisted suicide.

Symptoms Of Major Depression Relieved By St. John’s Wort

Wednesday, October 8th, 2008
New research provides support for the use of St. John's wort extracts in treating major depression. A Cochrane Systematic Review backs up previous research that showed the plant extract is effective in treating mild to moderate depressive disorders. "Overall, we found that the St.

AMPAKINE Compound, CX717, Achieves Primary Endpoints In Second Phase IIa Respiratory Depression Study In Germany

Tuesday, October 7th, 2008
Cortex Pharmaceuticals, Inc. (NYSE Alternext US (COR)) reported that top-line data from its second Phase IIa study in opioid-induced respiratory depression (RD) demonstrated that a single oral dose of 1500mg of the AMPAKINE® compound CX717 achieved statistical significance (p = 0.

Electromagnetic Biomarker Could Minimize Trial-And-Error Prescribing For Depression

Sunday, October 5th, 2008
Images of the brain's fastest signals reveal an electromagnetic marker that predicts a patient's response to a fast-acting antidepressant, researchers have discovered. "Such biomarkers that identify who will benefit from a new class of antidepressants could someday minimize trial-and-error prescribing and speed delivery of care for what can be a life-threatening illness," said Carlos Zarate, M.

How Can Physicians Recognize Depression At Early Stages? A New Method Is Suggested

Friday, October 3rd, 2008
A new method, based on clinical staging, has been suggested to identify depression at early stages and is described in the current issue of Psychotherapy and Psychosomatics. Depressive disorders are common and associated risks include the onset of secondary disorders, substance use disorders, impairment in social and occupational functioning, and an increase in suicidality.